Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Non-Current Deferred Tax Liability: 2014-2017

  • Vanda Pharmaceuticals' Non-Current Deferred Tax Liability fell 157.96% to -$386,000 in Q4 2017 from the same period last year, while for Dec 2017 it was -$386,000, marking a year-over-year decrease of 157.96%. This contributed to the annual value of -$386,000 for FY2017, which is 157.96% down from last year.
  • As of Q4 2017, Vanda Pharmaceuticals' Non-Current Deferred Tax Liability stood at -$386,000, which was down 157.96% from $666,000 recorded in Q4 2016.
  • Vanda Pharmaceuticals' Non-Current Deferred Tax Liability's 5-year high stood at $1.1 million during Q4 2015, with a 5-year trough of -$386,000 in Q4 2017.
  • For the 3-year period, Vanda Pharmaceuticals' Non-Current Deferred Tax Liability averaged around $460,000, with its median value being $666,000 (2016).
  • In the last 5 years, Vanda Pharmaceuticals' Non-Current Deferred Tax Liability skyrocketed by 18,233.33% in 2015 and then slumped by 157.96% in 2017.
  • Quarterly analysis of 4 years shows Vanda Pharmaceuticals' Non-Current Deferred Tax Liability stood at $6,000 in 2014, then skyrocketed by 18,233.33% to $1.1 million in 2015, then tumbled by 39.45% to $666,000 in 2016, then crashed by 157.96% to -$386,000 in 2017.
  • Its Non-Current Deferred Tax Liability was -$386,000 in Q4 2017, compared to $666,000 in Q4 2016 and $1.1 million in Q4 2015.